iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.
iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal; CiiEM - Interdisciplinary Research Center Egas Moniz, Instituto Universitário Egas Moniz, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal.
J Pharm Sci. 2022 Dec;111(12):3327-3339. doi: 10.1016/j.xphs.2022.08.023. Epub 2022 Aug 23.
Co-amorphization is a promising approach to stabilize drugs in the amorphous form. Olanzapine, a poorly water-soluble drug was used in this study. Sulfonic acids (saccharin, cyclamic acid and acesulfame), free and in salt forms, were used as co-formers and compared with carboxylic acids commonly used in the preparation of co-amorphous systems. Several manufacturing techniques were tested, and the co-amorphous systems characterized by differential scanning calorimetry, X-ray powder diffraction, thermogravimetry and Fourier-transform infrared spectroscopy. Free sulfonic acids produced co-amorphous systems with the drug, unlike their salts. Spectroscopy data suggests the formation of salts between olanzapine and the sulfonic acids, used as co-formers. The co-amorphous system produced with saccharin by solvent evaporation, showed the most notable solubility enhancement (145 times). The stability of amorphous and co-amorphous olanzapine systems was assessed upon exposure to stress conditions during storage. Amorphized olanzapine readily reconverted back to the crystalline form while sulfonic acids:olanzapine co-amorphous were stable for up to 24 weeks in low/medium humidity conditions (11-75% RH). Results highlight the potential advantages offered by sulfonic acids as co-formers to produce stable and more soluble co-amorphous olanzapine.
共晶化是一种将药物稳定在无定形状态的有前途的方法。在这项研究中使用了一种水溶性差的药物奥氮平。磺酸(糖精、环己烷酸和乙酰磺胺酸),无论是游离形式还是盐形式,都被用作共晶形成剂,并与通常用于制备共晶体系的羧酸进行了比较。测试了几种制造技术,并通过差示扫描量热法、X 射线粉末衍射、热重分析和傅里叶变换红外光谱对共晶体系进行了表征。与用作共晶形成剂的羧酸不同,游离磺酸可以与药物形成共晶体系。光谱数据表明,奥氮平和用作共晶形成剂的磺酸之间形成了盐。通过溶剂蒸发与糖精制成的共晶体系显示出最显著的溶解度增强(145 倍)。在储存过程中暴露于应激条件下,评估了无定形和共晶奥氮平体系的稳定性。无定形奥氮平很容易重新转化为结晶形式,而磺酸:奥氮平共晶在低/中湿度条件(11-75%RH)下稳定长达 24 周。结果突出了磺酸作为共晶形成剂的潜在优势,可用于制备稳定且更易溶的共晶奥氮平。